~~<i id='36FE057F90'><strike id='36FE057F90'><tt id='36FE057F90'><pre id='36FE057F90'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：explore 2025-09-06 07:37:48 Page View：6

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cloning humans is technically possible. It's curious no one has tried
Next article： Heart attack and stroke risk calculators need revising

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Louisiana bill approved classifying abortion pills as controlled substances

AllenG.Breed/APBATONROUGE—Twoabortion-inducingdrugscouldsoonbereclassifiedascontrolledanddangeroussu

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Gene therapy has helped boys walk. Can scientists keep it that way?

GenetherapyhelpedConnerCurran(atright)walk,butasthedrugfades,hisfamilyissupportingscientificeffortst